Elizabeth A. Stephens, M.D., Terri Ryan-Turek, R.D., C.D.E., and Juan P. Frias, M.D.
People with Type 1 diabetes and those with insulin-using Type 2 diabetes are deficient in secretion of amylin, a hormone cosecreted with insulin. The authors discuss why you and your patients might find the amylin analog pramlintide a useful adjunct to insulin if it receives FDA approval.
Drug treatment — Pramlintide
Robert E. Ratner, M.D.
Tight blood glucose control requires insulin administration that mimics a healthy pancreas. People with diabetes and their health-care team now have a wide array of options to make insulin administration easier and more convenient. This article compares newer systems to the traditional vial and syringe method and shows how to help your patients select and use these devices.
Drug treatment — Insulin
Diane M. Karl, M.D.
Fears of beta-cell burnout, hypoglycemia, and cardiovascular risks have raised concern about the use of sulfonylureas. Weighing the evidence, this article shows that not all sulfonylureas are created equal and that there is still a place for them in your antidiabetes arsenal.
Drug treatment — Sulfonylureas
William Hagopian, M.D., Ph.D., and Irl B. Hirsch, M.D.
Atypical presentations of the classic diabetes types have become increasingly common. Find out how identifying a patient’s specific pathophysiology and diabetes type could help you to prescribe individualized therapies that better slow or treat diabetes.
Ginger Kanzer-Lewis, R.N., B.C., Ed.M., C.D.E.
Balancing time constraints, safety, and patient’s need for education is a difficult task, but one that must somehow get done. Ms. Kanzer-Lewis explains how to organize your priorities and how your support and motivation can be critical to your patients’ health.